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Coxiella burnetii is a Gram-negative obligate intracellular pathogen and the causative agent of Q
fever in humans. Q fever causes acute flu-like symptoms and may develop into a chronic disease
leading to endocarditis. Its potential as a bioweapon has led to its classification as a category B
select agent. An effective inactivated whole-cell vaccine (WCV) currently exists but causes severe
granulomatous/necrotizing reactions in individuals with prior exposure, and is not licensed for use
in most countries. Current efforts to reduce or eliminate the deleterious reactions associated with
WCVs have focused on identifying potential subunit vaccine candidates. Both humoral and T cell-
mediated responses are required for protection in animal models. In this study, nine novel
immunogenic C. burnetii proteins were identified in extracted whole-cell lysates using 2D
electrophoresis, immunoblotting with immune guinea pig sera, and tandem MS. The immunogenic
C. burnetii proteins elicited antigen-specific IgG in guinea pigs vaccinated with whole-cell killed
Nine Mile phase I vaccine, suggesting a T cell-dependent response. Eleven additional proteins
previously shown to react with immune human sera were also antigenic in guinea pigs, showing
the relevance of the guinea pig immunization model for antigen discovery. The antigens described
here warrant further investigation to validate their potential use as subunit vaccine candidates.
INTRODUCTION
Coxiella burnetii is an obligate intracellular Gram-negative
bacterium that resides and replicates within phagolyso-
somes (Voth & Heinzen, 2007). C. burnetii infections may
be asymptomatic or present as an influenza-like illness in
humans termed acute Q fever (Maurin & Raoult, 1999).
Acute Q fever is generally self-limiting, but a chronic, latent
infection may persist for years, leading to chronic Q fever
or endocarditis in response to reactivation-triggering
events such as immunosuppression (Maurin & Raoult,
1999). Mortality rates in the general population from Q
fever are 1–2% with a much higher incidence of death
associated with pregnant women and individuals with
preexisting valvulopathies (Maurin & Raoult, 1999).
Domestic animals, arthropods and humans all serve as
reservoirs for C. burnetii, which is shed in milk, urine,
faeces and during parturition (Arricau Bouvery et al., 2003;
Maurin & Raoult, 1999). The primary vector of transmis-
sion to humans appears to be contaminated sheep, cattle
and goats. C. burnetii is highly infectious (infective dose
,10), produces variants that are extremely stable in the
environment, and is easily disseminated and transmitted by
aerosols and dust particles. The United States Center for
Disease Control has deemed C. burnetii a potential
bioterrorism threat and classified it as a category B select
agent.
C. burnetii has an LPS layer that undergoes phase variation
upon repeated serial passage analogous to the smooth LPS
to rough LPS transition of Gram-negative enteric bacteria
(Hackstadt et al., 1985). The transition to truncated
smooth phase II LPS has been attributed to an 18 kb
genomic deletion (Vodkin & Williams 1986). Products of
genes associated with the deleted region possess homology
to proteins known to be involved in sugar conversions and
the synthesis of LPS (Hoover et al., 2002). The difference in
virulence between phase I (virulent) and phase II
(avirulent) clonal variants appears to be due to the
Abbreviations: ACN, acetonitrile; CMRV, chloroform, methanol residue
vaccine; IFA, incomplete Freund’s adjuvant; IPG, immobilized pH
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that are absent in phase II clones (Hackstadt et al., 1985).
Inactivated whole-cell C. burnetii phase I vaccine prepara-
tions are effective at protecting vaccinees from subsequent
C. burnetii infection, while inactivated whole-cell phase II
preparations are not. A formalin-inactivated whole-cell
phase I vaccine is commercially available (Q-Vax), but no
vaccine for Coxiella is currently licensed for use in the USA.
Protective whole-cell vaccines (WCVs) may produce
adverse reactions that include delayed-type hypersensitiv-
ity/necrotizing reactions at the site of injection in
individuals with prior exposure to C. burnetii, and the risk
of adverse reactions increases with subsequent immuniza-
tions. A chloroform:methanol residue vaccine (CMRV) of
C. burnetii phase I cells has been found to confer protection
against subsequent C. burnetii challenge in a number of
animal models (Williams & Cantrell, 1982; Waag et al.,
1997, 2002) and reduces the adverse reactions associated
with the WCV (Ascher et al., 1983). The adverse reactions
from this extracted preparation are still considered too
severe for licensure in the USA. Since a CMRV reduces the
severity of reactions yet still induces a protective immune
response, it is plausible that an effective subunit vaccine
can be developed to further reduce or eliminate these
adverse reactions.
Vaccination with a WCV or CMRV induces T cell
proliferation, seroconversion and protection against lethal
challenge (Williams et al., 1986; Waag et al., 1997, 2002).
Protein components and not LPS are responsible for T cell
proliferation (Izzo et al., 1991). Protective immunity
against Coxiella can be transferred to naı ¨ve animals by
CD4
+ T cells or serum from WCV- or CMRV-vaccinated
animals (Andoh et al., 2007; Zhang et al., 2007). The
mechanism of antibody-mediated immunity to C. burnetii
infections is not clear but does not involve activating Fc
receptors or complement (Shannon et al., 2009).
Guinea pigs infected with C. burnetii consistently mimic
clinical and pathological symptoms seen in human acute Q
fever, exhibiting enlarged spleen and lymph nodes,
granulomas in liver, bone marrow and spleen, detectable
bacteraemia, fever, and similar dose/response effects
(Maurin & Raoult, 1999; Russell-Lodrigue et al., 2006).
The robustness of the guinea pig model has also
demonstrated differences in virulence between C. burnetii
genogroups (Russell-Lodrigue et al., 2009). Importantly,
guinea pigs display consistent lethal dose–responses to
aerosol challenge (Waag et al., 1997) but are protected by
WCV vaccination (Waag et al., 2002), which results in
intense delayed-type hypersensitivity and dermal granulo-
matous reactions (Ascher et al., 1983).
This study was conducted to identify and further expand
the number of C. burnetii Nine Mile proteins that generate
a T cell-dependent IgG response in the guinea pig model.
Newly identified immunogenic proteins may be of value in
developing a subunit vaccine against C. burnetii infection
as well as serodiagnostic targets.
METHODS
Growth and preparation of C. burnetii RSA 493 Nine Mile phase
I whole-cell killed vaccine (WCKI). C. burnetii NMI RSA 493
(phase I) was grown in embryonated chicken yolk sacs and purified
by differential sedimentation using sucrose density gradients, as
described by Hendrix & Mallavia (1984). Purified phase I cells were
inactivated by electron beam irradiation with a minimum 10 kGy
dose and tested for non-viability in a severe combined immunodefi-
ciency (SCID) mouse model as described previously (Andoh et al.,
2003), and used for 2D analysis and for WCKI vaccination of guinea
pigs. C. burnetii RSA 493 Nine Mile phase I (clone 7) and its phase II
clone RSA 439 (clone 4) were grown in mouse L929 fibroblast cell
cultures and purified by gradient centrifugation, as reported by
Williams et al. (1981). Phase I, but not phase II, cells were similarly
inactivated by irradiation and tested for non-viability in SCID mice.
For all sources of bacteria, bacterial concentrations were determined
as dry weight of organisms, and bacteria were resuspended in PBS
containing 0.25 M sucrose and used for 2D analysis.
Animals, immunization and serum collection. Six female Hartley
outbred guinea pigs were obtained from Charles River Laboratories.
WCKI was emulsified in a 1:1 ratio of incomplete Freund’s adjuvant
(IFA) (Sigma) and 0.9% sterile NaCl. Three animals were each
immunized with 30 mg WCKI delivered subcutaneously into each rear
flank at a concentration of 15 mg 125 ml
21. Three different animals
received 125 ml emulsified IFA and 0.9% sterile NaCl (1:1) delivered
subcutaneously into each rear flank (sham-immunized). Animals
were boosted twice more at 2 week intervals using their respective
protocol. Three days after the final boost, animals were euthanized
with 400 ml Beuthanasia-D (Schering-Plough) delivered intraperito-
neally and exsanguinated to collect serum. Following centrifugation,
individual sera were stored at 220 uC as frozen aliquots. Prior to
immunoblotting, the sera from the three WCKI-immunized guinea
pigs were pooled using equal volumes (immune sera). Similarly, the
sera from the three sham-immunized guinea pigs were pooled using
equal volumes (sham sera). The same pooled immune sera and
pooled sham sera were used throughout this study. All protocols
involving animals were reviewed and approved by the Washington
State University Institutional Animal Care and Use Committee.
Whole-cell C. burnetii protein extraction and preparation for
2D electrophoresis. C. burnetii phase I or phase II cells (6 mg dry
weight equivalent) in PBS with 0.25 M sucrose (0.25 M SP buffer)
were centrifuged at 6000 g for 10 min at room temperature to pellet
cells. The supernatant was discarded and pelleted cells were washed by
gently resuspending them in cold Tris-buffered saline (TBS; 50 mM
Tris/HCl, 150 mM NaCl, pH 7.4) and recentrifugation. Pelleted cells
were resuspended in 250 ml Bio-Rad Ready Prep Sequential
Extraction Buffer #1 (40 mM Tris base, pH 8.8) containing 60 U
benzonase (Sigma-Aldrich), 16 Halt proteinase inhibitor (Thermo
Scientific) and 2 mM MgCl2, and were sonicated with four 30 s pulses
at 200 W. Sonicated cells were vortexed for 2 min, incubated for
3 min at room temperature, and this was repeated four times.
Samples were then centrifuged at 20800 g for 15 min to pellet
insoluble material. Supernatant was collected and transferred to a
fresh microfuge tube. Sequential Extraction Buffer #3 (150 ml) (Bio-
Rad) containing 2 mM of the reducing agent tributyl phosphine
(TBP) was added to the pelleted unsolubilized material. The tube was
then vortexed for 2 min, incubated at room temperature for 3 min,
and this was repeated four times. Tubes were spun at 20800 g for
15 min at 20 uC. The supernatant was collected and pooled with the
previous supernatant. The pelleted unsolubilized material was
reextracted two more times using 125 ml aliquots of Sequential
Extraction Buffer #3 with TBP following the same procedure and
pooling all supernatants. The pooled supernatant extract was directly
reduced and alkylated using the ReadyPrep Reduction-Alkylation kit
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extract was aliquoted equally into six microfuge tubes and cleaned
using the Bio-Rad ReadyPrep 2-D Cleanup kit according to the kit
instructions. Cleaned pellets were resuspended in fresh rehydration
buffer [5 M urea, 2 M thiourea, 2 mM TBP, 2% (w/v) CHAPS and
2% (w/v) 3-(decyldimethyl-ammonio) propanesulfonate inner salt
(detergent SB 3-10, Sigma)] with vortexing and combined into one
microfuge tube (total volume 750 ml). The extracted protein
concentration was determined using the Bio-Rad RC/DC protein
assay.
2D Electrophoresis. pH 5–8 or pH 3–10 linear gradient ReadyStrip
immobilized pH gradient (IPG) strips (11 cm, Bio-Rad) were
passively rehydrated overnight with 250 mg whole-cell extracted
protein in a volume of 200 ml rehydration buffer supplemented with
0.2% (w/v) Bio-Lyte 3–10 ampholytes, 0.001% (w/v) bromophenol
blue, and 2 mM TBP, as per the IPG strip instruction manual.
Electrophoresis of IPG strips was conducted on a Protean IEF Cell
(Bio-Rad) for a total of 40000 V h. Focused IPG strips were removed
and equilibrated in SDS-PAGE buffer, utilizing the reduction/
alkylation procedure described in the IPG strip manual. Second-
dimension electrophoresis was done on Criterion 10.5–14% Tris/HCl
acrylamide gels (Bio-Rad). Gels for protein spot harvesting and liquid
chromatography-tandem MS (LC-MS/MS) analysis were fixed in
10% methanol, 7% acetic acid for 45 min, washed briefly in distilled
H2O, and stained overnight in Sypro Ruby gel stain (Bio-Rad) with
orbital shaking. Stained gels were destained in 10% methanol, 7%
acetic acid for 1 h, washed in distilled H2O and imaged with Quantity
One software on a Pharos FX imager (Bio-Rad), and the gel images
were printed. Gels were stored covered and in distilled H2Oa t4uC.
Immunoblotting and protein spot harvesting. Parallel gels for
immunoblotting were transferred to PVDF membranes (0.45 mm,
Perkin Elmer) using cold Tris-glycine 20% methanol transfer buffer.
PVDF membranes were dried overnight, stained with Sypro Ruby blot
stain (Bio-Rad) according to the manufacturer’s instructions and
imaged with Quantity One software on a Pharos FX imager (Bio-
Rad), and the blot images were printed. Immunoblots were then
blocked in blocking buffer [0.2% I Block (Tropix) and 0.1% Tween
20 in PBS] for 1 h. Blots were probed in blocking buffer with a 1:200
dilution of pooled immune sera or a 1:100 dilution of pooled sham
sera, incubated for 1.5 h, and washed four times for 5 min each in
blocking buffer. Blots were incubated for 1 h with peroxidase-
conjugated rabbit anti-guinea pig IgG (whole molecule) (Sigma)
diluted 1:15000 in blocking buffer and washed five times for 5 min
each followed by two quick washes in distilled H2O. Blots were
developed using ECL Western Blotting Substrate (Pierce) and
exposed to Biomax XAR films (Kodak).
2D Gel and immunoblot spot matching. Exposed film was overlaid
and aligned on the matching blot and immunoreactive spots were
outlined by perforating with a 28 gauge needle. Perforated spots were
excised using a scalpel. Excised blots were rescanned with Quantity
One software on a Pharos FX imager and printed. Excised blots
produce a white void where the excised blot pieces were removed that
facilitates identifying immunoreactive spots on the stained blot by
overlaying the stained blot image on the excised blot image on a
standard light box. Immunoreactive spots on the stained blot image
can then be precisely identified. PDQuest version 8.1 (Bio-Rad) 2D
analysis software was used to align Sypro Ruby-stained blot images
and stained gel images to match spots. Images were warped and spot
centres were fitted by Gaussian modelling. Spots were normalized
using the local regression model. Spots were matched using the
PDQuest match tool. Neighbouring spot patterns and spot intensities
were also examined using the PDQuest 3D analysis tool for additional
confirmation of correct spot matching. Matched spots were identified
and marked on corresponding printed gel images and used as a
reference document when manually excising gel spots. Sypro Ruby-
stained gels were made to fluoresce using a UV light box, and
corresponding immunoreactive spots were removed using a number
11 scalpel and transferred to sterile microfuge tubes. Gel pieces were
briefly centrifuged and liquid removed, and then stored at 220 uC
until digested with trypsin.
In-gel trypsin digestion. Gel pieces were washed in 100 ml5 0 %
acetonitrile (ACN), 50% NH4HCO3 (pH 8.0) and centrifuged, and
the wash solution was discarded. Gel pieces were dehydrated in 300 ml
100% ACN and centrifuged, and ACN was removed, and gel pieces
were air-dried for 5 min. Dehydrated gel pieces were rehydrated in a
3 ml solution of sequencing-grade modified trypsin (Promega) in
50 mM NH4HCO3 (50 mgm l
21) for 15 min. An additional 20 mlo f
50 mM NH4HCO3 was then added to cover and fully swell gel pieces,
which were incubated stationary for 16 h at 37 uC. Digestion
reactions were vortexed for 3 min and centrifuged, and supernatants
were transferred to sterile microfuge tubes and placed at 4 uC. Gel
pieces were extracted with 0.1% trifluoroacetic acid (TFA) for 45 min
at 37 uC, vortexed for 4 min and centrifuged, and supernatants were
pooled with previously collected supernatant. Gel pieces were
similarly sequentially reextracted with 30% ACN, 0.1% TFA for
45 min and 60% ACN for 30 min. All corresponding supernatants
were pooled and dried down to approximately 20 ml in a SpeedVac
concentrator.
MS and sequence analysis of tryptic peptide fragments. LC-
MS/MS analysis of tryptic peptides performed at the Environmental
Biotechnology Institute, University of Idaho, was as described by
Bansal et al. (2009). Briefly, solvent A was 0.1% formic acid in water
and solvent B was 0.1% formic acid in ACN. Peptides were trapped
on a 180 mm620 mm Symmetry C18 5 mm trap column (Waters)
prior to injection into a 75 mm6200 mm BEH 130 C18
nanoACQUITY Ultra Performance Liquid Chromatograph column
(Waters). Flow rate was 0.4 ml min
21 and starting solvent concentra-
tions were 95% A and 5% B with an increase in B concentration to
50% by 44 min. Solvent B was then increased to 90% over 5 min and
held for an additional 5 min, then returned to 5% over the next
5 min. A Micromass Q-TOF Premier tandem mass spectrometer
(Waters) using electrospray ionization generated peptide sequence
data. Raw peptide data files were converted to peak list files and
uploaded to our local Mascot 2.1.0 (Matrix Science) server and
searched against the National Center for Biotechnology Information
(NCBI) non-redundant all entries database (20090217) and the
annotated C. burnetii RSA 493 complete genome database (Seshadri
et al., 2003).
Tryptic peptide analysis by LC-MS/MS at the Laboratory for
Biotechnology and Bioanalysis 2 at Washington State University
was as described by Lopez et al. (2005) with peptide separations as
modified by Noh et al. (2008). Briefly, an Esquire HCT electrospray
ion trap (Bruker Daltonics) with a C18 PepMap, 300 mm61 mm,
5 mm trap column (LC Packings/Dionex) was used with an Ultimate
Nano high pressure liquid chromatography system (LC Packings/
Dionex). Peptides were separated on a polystyrene-divinylbenzene
(PS-DVB) monolithic column (LC Packings/Dionex). Solvent A was
0.1% formic acid, 3% ACN. Solvent B was 0.1% formic acid, 95%
ACN. The flow rate was 800 nl min
21 with a solvent A to B linear
gradient change that reached 65% solvent B at 95 min and then
100% solvent B at 95.1 min, and held at 100% solvent B until
115 min. Data were acquired in Bruker Auto (MS2) mode. Peptide
sequence files were uploaded to our internal Mascot 2.1.0 (Matrix
Science) server and searched against the NCBI non-redundant
database (20090217) limited to lobed-finned fish and tetrapod clade,
Mus and/or human, and the annotated C. burnetii RSA 493 complete
genome database (Seshadri et al., 2003).
J. R. Deringer and others
528 Microbiology 157RESULTS
2D Electrophoresis and immunoblotting of phase
I whole-cell extracts
Initial attempts to identify immunogenic C. burnetii Nine
Mile phase I proteins were conducted using whole-cell
protein extracts of phase I organisms grown in embryonated
chicken yolk sacs [phase I (egg)]. Four replicate pH 3–10
gradient blots were probed with immune sera and two
replicate blots were probed with sham sera. Representative
immune sera and sham sera probed blots are shown in Fig.
1(a and b), respectively. Spots identified as C. burnetii
proteins are numbered. Sham-sera-reactive spot N4 had no
detectable reactivity on any immune sera-probed blots and
is included in Fig. 1(a) as a point of reference.
A total of 34 reactive spots were analysed by LC-MS/MS.
Of the reactive spots, 24 were identified as chicken (Gallus)
proteins (data not shown), seven spots were identified as C.
Fig. 1. Immunoblots of whole-cell extracts of C. burnetii RSA 493 phase I grown in hen yolk sacs and separated by 2D gel
electrophoresis on pH 3–10 IEF gradients and 10.5–14% acrylamide SDS-PAGE gels. Labelled spots represent C. burnetii
seroreactive proteins identified by LC-MS/MS and are listed in Table 1. Molecular mass standards (kDa) are indicated on the
left. (a) Immunoblot probed with pooled immune guinea pig serum. Spot N4 was not reactive with immune sera and is included
for reference. (b) Immunoblot probed with pooled serum from sham-immunized guinea pigs.
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and three spots could not be identified. The antigenic C.
burnetii proteins were CBU1706 (thioredoxin peroxidase),
CBU1290 (DnaK), CBU1910 (com1) and CBU0229 (ribo-
somal protein L7/L12). CBU0495 (FabG) and CBU0780/
CBU0955(bothresponseregulatorGacA)wereco-identified
with CBU1910 in spots 15 and 18, respectively. The sham
sera-reactive spot N4 was identified as CBU0263 (RpoA).
2D Electrophoresis, immunoblotting, and LC-MS/
MS identification of phase II L929 proteins
separated on pH 3–10 gradient gels
It is not uncommon to co-purify host cell proteins when
isolating bacteria from an intracellular source (Ogawa et al.,
2007). Since phase I organisms isolated from hen yolk sacs
were used to immunize animals and generate immune sera,
the detection of antibody-reactive chicken proteins in
phase I extracts is not surprising. To reduce our immune
sera reactivity to non-Coxiella antigens, whole-cell protein
extracts of C. burnetii Nine Mile RSA 439 grown in murine
L929 (phase II L929) cell cultures were used. RSA 439 is the
phase II clone of RSA 493 phase I, with the only known
difference in proteomes between these two strains resulting
from the genomic deletion encompassing loci CBU0678 to
CBU0698 [The Institute for Genomic Research (TIGR)
annotation] associated with the truncated LPS of phase II
organisms (Hoover et al., 2002). The only known
difference in protein antigen seroreactivity between these
two clones to phase-I-derived immune sera is due to a
21 kDa proteinase K-sensitive antigen that is uniquely
reactive in extracts of phase I (Zhang et al., 2007).
A Sypro Ruby-stained pH 3–10 gradient 2D gel of C.
burnetii Nine Mile RSA 439 phase II whole-cell protein
extract is shown in Fig. 2(a) (representative of three gels).
The numbered gel spots correspond to antibody-reactive
spots on blots probed with immune sera (Fig. 2b,
representative of three replicates) and sham sera (Fig.
2c). The C. burnetii proteins identified are listed in Table 2.
Examination of gel and blot images using the 3D viewer
function of PDQuest showed distinct vertical troughs at the
apparent boundary of the isoelectric gradient. Immuno-
reactive spots 1 and 49 were outside this boundary,
migrated with the same apparent molecular mass as spot
14, and were similarly identified as CBU1290 (DnaK) and
CBU0235 (EF-G). Reactive spots 3, 40 and 41 were also
located outside the trough boundary and correlate with the
molecular mass of reactive spots 37, 39 and 39.5, and were
similarly identified as CBU1910 (com1). It appears that
sample in the portion of the IPG strip beyond the
electrodes is not focused in the first dimension but only
in the second dimension. Reactive spot 2 was outside the
trough, migrated with the same molecular mass as reactive
spot 15, but was not identified as a protein in spot 15. This
may be due to spot 2 being composed of all proteins with
an approximate molecular mass of 46 kDa and the
difficulties that this presents for detection by LC-MS/MS,
particularly if the protein of interest is underrepresented or
its peptides are more difficult to ionize. Spot 15 comprised
multiple reactive doublets that were difficult to harvest
individually and were harvested together to add some
degree of confirmation to subsequent LC-MS/MS analysis.
Spot 15 comprised CBU0215 (peptidase), CBU0572
(cytosol aminopeptidase) and CBU1398 (SucB). LC-MS/
Table 1. Phase I (egg) C. burnetii Nine Mile RSA 493 proteins identified by LC-MS/MS in seroreactive spots separated on pH 3–10
gradient gels
Spot
no.*
Locus tagD Putative proteind Protein
score§
Sequence
coverage
No. of unique
peptides with P
value ,0.05||
Predicted Mr
(kDa)/pI
13 CBU1706 Thioredoxin peroxidase, AhpC/Tsa family 71 20% 2 21.8/5.08
14 CBU1290 DnaK chaperone 116 13% 1 70.7/5.14
15 CBU0495 3-Oxoacyl-(acyl-carrier-protein) reductase FabG 112 14% 2 26.3/7.63
CBU1910 com1 65 14% 1 27.6/9.08
17 CBU1910 com1 55 14% 1 27.6/9.08
18 CBU1910 com1 165 23% 3 27.6/9.08
CBU0780 DNA-binding response regulators GacA 54 6% 1 24.2/9.10
CBU0955 6% 1 24.1/9.52
27 CBU0229 Rp1L ribosomal protein L7/L12 84 38% 1 13.2/4.71
N4 CBU0263 RpoA DNA-directed RNA polymerase, alpha 205 12% 4 35.5/5.61
*Corresponds to spot shown in Fig. 1.
DTIGR annotation.
dDescribed in Beare et al. (2009), Supplemental file 1, Supplemental Table S5.
§Mascot protein scores (standard scoring) are derived from combined peptide ion scores as a non-probabilistic basis for ranking protein hits.
||The number of unique peptides identified with ion scores .24 that indicate identity or extensive homology (P,0.05). Ion score is 2106log(P),
where P is the probability that the match is a random event.
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530 Microbiology 157Fig. 2. Whole-cell extracts of C. burnetii RSA 439 phase II grown in mouse L929 cell culture and separated by 2D gel
electrophoresis on pH 3–10 IEF gradients and 10.5–14% acrylamide SDS-PAGE gels. C. burnetii seroreactive proteins are
listed in Table 2. Molecular mass standards (kDa) are indicated on the left. (a) Sypro Ruby-stained gel showing seroreactive
spots. Immune sera-reactive spots are labelled with numbers alone. Sham sera-reactive spots are labelled with numbers with an
N prefix. (b) Immunoblot probed with pooled immune guinea pig serum. Spot numbers with an N prefix were also sham sera-
reactive. (c) Immunoblot probed with pooled serum from sham-immunized guinea pigs.
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included in Table 2.
Several immune sera-reactive spots were identified as one
protein: spot 9 (CBU0229, ribosomal protein L7/L12), spot
16 (CBU0236, EF-Tu), spot 17 (CBU0092, Tol system
component YbgF), spot 18 (CBU1241, malate dehydro-
genase), spot 19 (CBU0092, Tol–Pal system component
YbgF), spot 34 (CBU0299, Rph RNase), spots 37, 39 and
39.5 (CBU1910, com1), and spot 55 (CBU0937, hypothet-
ical exported protein). All other immune sera-reactive
phase II spots analysed from pH 3–10 gradient gels
identified more than one protein.
Spot 20 was identified as CBU1396 (SucD) and CBU0092
(Tol system component YbgF). CBU1910 (com1) was
identified in all immune sera-reactive spots that focused on
the cathode side of the gel with apparent molecular masses
of approximately 25 kDa (spots 32, 33 and 35–39.5). The
spots identified as only CBU1910 (com1) (spots 37, 39 and
39.5) all displayed the same apparent molecular mass that
appeared to be slightly less than that of spots 32 and 33.
Table 2. Phase II C. burnetii Nine Mile proteins identified by LC-MS/MS in seroreactive spots separated on pH 3–10 gradient gels
Spot
no.*
Locus tagD Protein annotationd Protein
score§
Sequence
coverage
No. of unique
peptides with P
value ,0.05||
Predicted Mr
(kDa)/pI
9 CBU0229 Rp1L ribosomal protein L7/L12 391 63% 5 13.2/4.71
14 CBU1290 DnaK chaperone 266 27% 4 70.7/5.14
CBU0235 FusA elongation factor EF-G 247 26% 4 77.7/5.07
15 CBU0215 Peptidase, C40/NplC-P60 family 142 17% 2 58.0/6.06
CBU0572 Cytosol aminopeptidase 228 36% 4 50.8/5.56
CBU1398 SucB dihydrolipoamide succinyltransferase 170 30% 2 45.9/5.54
16 CBU0236 Elongation factor EF-Tu 887 70% 14 43.5/5.32
17 CBU0092 Tol system component YbgF 60 22% 1 32.0/5.49
18 CBU1241 Mdh malate dehydrogenase 120 25% 2 35.4/5.07
19 CBU0092 Tol system component YbgF 72 18% 1 32.0/5.49
20 CBU1396 SucD succinyl-CoA synthetase, alpha subunit 187 36% 3 30.6/5.38
CBU0092 Tol system component YbgF 89 26% 1 32.0/5.49
32 CBU1227 Transcriptional regulatory protein QseB 108 29% 1 25.2/7.88
CBU1910 com1 88 20% 2 27.6/9.08
33 CBU1227 Transcriptional regulatory protein QseB 129 22% 1 25.2/7.88
CBU1910 com1 101 13% 2 27.6/9.08
CBU0481 Arginine transport ATP-binding protein ArtP 66 34% 1 27.8/8.37
34 CBU0299 Rph RNase PH 136 36% 2 25.9/7.75
35 CBU1227 Transcriptional regulatory protein QseB 163 22% 2 25.2/7.88
CBU1910 com1 218 29% 3 27.6/9.08
36 CBU1910 com1 239 18% 3 27.6/9.08
CBU0495 3-Oxoacyl-(acyl-carrier-protein) reductase FabG 157 26% 2 26.3/7.63
CBU1227 Transcriptional regulatory protein QseB 74 17% 1 25.2/7.88
37 CBU1910 com1 288 32% 4 27.6/9.08
37.5 CBU1910 com1 282 24% 4 27.6/9.08
CBU0482 Arginine-binding protein, periplasmic 156 16% 2 29.8/9.40
38 CBU1910 com1 331 31% 4 27.6/9.08
CBU0481 Arginine transport ATP-binding protein ArtP 75 36% 1 27.8/8.37
39 CBU1910 com1 145 24% 3 27.6/9.08
39.5 CBU1910 com1 167 28% 3 27.6/9.08
55 CBU0937 Conserved hypothetical protein 513 33% 9 51.3/8.99
N41 CBU0263 RpoA DNA-directed RNA polymerase, alpha 283 47% 3 35.5/5.61
N42 CBU0236 Elongation factor EF-Tu 216 50% 2 43.5/5.32
CBU0263 RpoA RNA polymerase, alpha 80 34% 0 35.5/5.61
N43 CBU0263 RpoA RNA polymerase, alpha 156 37% 1 35.5/5.61
*Corresponds to spot shown in Fig. 2.
DTIGR annotation.
dDescribed in Beare et al. (2009), Supplemental file 1, Supplemental Table S5.
§Mascot protein scores (standard scoring) are derived from combined peptide ion scores as a non-probabilistic basis for ranking protein hits.
||The number of unique peptides identified with ion scores .24 that indicate identity or extensive homology (P,0.05). Ion score is 2106log(P),
where P is the probability that the match is a random event.
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com1, this indicates the primary protein represented by
spots 32 and 33 is not com1. LC-MS/MS analysis of spots
32 and 33 did identify CBU1227 (transcriptional regulatory
protein QseB) as the highest-scoring protein in both.
Additionally, CBU0481 (arginine transport ATP-binding
protein) was identified in spot 33. Spot 35 was identified as
CBU1910 (com1) and CBU1227 (QseB). Spot 36 was a
fairly abundant protein on stained gels and was identified
as CBU1910 (com1), CBU0495 (FabG) and CBU1227
(QseB). The cathode side of spot 36 was designated spot
37, but more accurately should be described as the cathodic
shoulder of spot 36 and was only identified as CBU1910
(com1). Similarly, spot 37.5 should be more accurately
described as the anodic shoulder of spot 38. Analysis of
both spot 37.5 and spot 38 identified CBU1910 (com1) as
the highest Mascot-scoring protein. Spot 37.5 also
contained CBU0482 (arginine-binding protein), while spot
38 co-identified CBU0481 (arginine transport ATP-bind-
ing protein). Spots 37, 37.5, 38 and 39 also identified
CBU0578 (polyprenyl-phosphate b-D-glucosyltransferase)
with Mascot scores that were significant (non-probalistic)
by mudpit but not by standard scoring, and were omitted
from Table 2. Interestingly, one peptide assigned to
CBU0578 was detected in spots 37 and 37.5 with ion
scores above the P,0.05 threshold, with intensities of
21627 and 41608, respectively, which were much higher
than those of most peptides analysed in this study.
The blot probed with sera from sham-immunized guinea
pigs was overexposed to assess cross-reacting antibody
responses elicited by IFA in saline without antigen (Fig.
2c). Sham sera had very strong reactivity to three spots
with the same molecular mass but slight differences in pI,
spots N41, N42 and N43. The only protein identified in
spots N41 and N43 was CBU0263 (RpoA). CBU0263
(RpoA) was also identified in spot N42. However, the
highest-scoring protein identified in spot N42 was
CBU0236 (EF-Tu). No immune-sera-reactive spots coin-
cided with the location of spot N41 or spot N43, but the
location of sham sera spot N42 did coincide with a weakly
reactive spot on the immune sera-probed blot at a
molecular mass less than the theoretical molecular mass
of EF-Tu. Immune sera reactivity of this spot is most likely
due to an unidentified protein and not EF-Tu. Strong sham
sera reactivity was also detected on the horizontally diffuse
spot N12, which was matched to immune sera-reactive
spot 9, identified as CBU0229 (ribosomal protein L7/L12).
Spots N50, N51 and N52 had weak sham sera reactivity and
were also matched to immune sera-reactive spots, and were
not analysed by LC-MS/MS. With the exception of spots
N12, N42, N50, N51 and N52, no other numbered immune
sera-reactive spots were matched to sham sera-reactive
spots, indicating that the immune sera reactivity to these
proteins is C. burnetii-specific.
To achieve greater spot separation and in an attempt to
reduce the number of reactive spots with co-identified
proteins, subsequent phase II (L929) extracts were run on
narrower IEF gradients (pH 5–8) with longer second
dimension runs.
2D Electrophoresis, immunoblotting, and LC-MS/
MS identification of phase II L929 proteins
separated on pH 5–8 gradient gels
A Sypro Ruby-stained pH 5–8 gradient 2D gel of phase II
proteins is shown in Fig. 3(a), representative of two
replicates. The numbered spots on the gel correspond to
matched antibody-reactive spots detected on the blots
probed with immune sera shown in Fig. 3(b) (represent-
ative of two replicates) and sham sera shown in Fig. 3(c).
Two immune sera-reactive spots were detected past the
vertical trough boundaries. Based on our previous
observations and identification of reactive proteins located
outside the trough, these spots were not analysed by LC-
MS/MS. Reactive proteins identified by LC-MS/MS are
listed in Table 3.
Immune sera-reactive spot 14 seen on pH 3–10 gradient
gels resolved into five reactive pI isoforms (spots 14.1–
14.5) when separated on pH 5–8 gradient gels. These spots
were all identified as comprising CBU1290 (DnaK) and
CBU0235 (EF-G), with the exception of spot 14.4, in which
only CBU1290 (DnaK) was identified. Reactive spot 16,
identified as CBU0236 (EF-Tu) on the pH 3–10 gel,
resolved into three reactive pI isoforms (spots 16.2, 16.3
and 16.4), all of which were identified as CBU236 (EF-Tu).
Reactive spot 20 on the pH 3–10 gradient gel (identified as
CBU1396 and CBU0092) resolved into two spots when
separated on pH 5–8 gradient gels, designated spots 20 and
20.1. Spots 20 and 19 from the pH 5–8 gradient gel were
identified as CBU0092 (Tol system component YbgF).
Spots 20.1 and 19.1 were identified as CBU1396 (SucD).
Spot 18 was identified as CBU1241 (malate dehydrogenase).
CBU0236 EF-Tu was identified in spot 17. However, the
apparent molecular mass of spot 17 was much lower than
the theoretical molecular mass of EF-Tu and most likely is
not responsible for the reactivity of this spot. Spot 23 was
identified as CBU1385 (EF-Ts) and spot 34 identified as
CBU0750 (arabinose-5-phosphate isomerase). Spots 28 and
29 were identified as CBU0103 (peptidase M20A). Weakly
immune sera-reactive spots 24, 26 and 27 were identified
as CBU0528 (ribosomal protein S1), CBU0858 (gluta-
mine-dependent NAD
+ synthase) and CBU1943 (ATP
synthase F1, alpha subunit), respectively. Spots 15.1–15.8,
analogous to spot 15 on the pH 3–10 gradient gel,
appeared as reactive doublets. Interestingly, spot 15.1
was identified as CBU1718 (GroEL), and focused at a
lower molecular mass and with a slightly more basic pI
than its theoretical values. No proteins could be conclu-
sively identified in spot 15.2. CBU0215 (peptidase) and
CBU1398 (SucB) were identified in all other remaining 15
series spots with the exception of spots 15.3 and 15.4,
which were identified as CBU0215 only. Spot 15.7
additionally contained CBU0932 (glycerol kinase) and
CBU0572 (cytosol aminopeptidase).
Immunoreactive Coxiella burnetii proteins
http://mic.sgmjournals.org 533Fig. 3. Whole-cellextractsofC.burnetiiRSA439phaseIIgrowninmouseL929cellcultureandseparatedby2Dgelelectrophoresis
on pH 5–8 IEF gradients and 10.5–14% acrylamide SDS-PAGE gels. C. burnetii seroreactive proteins are listed in Table 3.
Molecular mass standards (kDa) are indicated on the left. (a) Sypro Ruby-stained gel showing seroreactive spots. Immune sera-
reactive spots are labelled with numbers alone. Sham sera-reactive spots are labelled with numbers and an N prefix. (b) Immunoblot
probed with pooled immune guinea pig serum. (c) Immunoblot probed with pooled serum from sham-immunized guinea pigs.
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534 Microbiology 157The spot designated NS was very abundant on all gels but
was not noticeably reactive above non-specific background
levels on previous immune sera-probed blots. The
reactivity of spot NS shown in Fig. 3(b) is greater than
that previously detected. In view of the abundance of this
protein on gels, the level of reactivity of this spot was
Table 3. Phase II C. burnetii Nine Mile proteins identified by LC-MS/MS in seroreactive spots separated on pH 5–8 gradient gels
Spot
no.*
Locus tagD Putative proteind Protein
score§
Sequence
coverage
No. of unique
peptides with
P value ,0.05||
Predicted Mr
(kDa)/pI
14.1 CBU0235 FusA elongation factor EF-G 251 26% 4 77.7/5.07
CBU1290 DnaK chaperone 94 26% 2 70.7/5.14
14.2 CBU0235 FusA elongation factor EF-G 316 12% 5 77.7/5.07
CBU1290 DnaK chaperone 231 6% 4 70.7/5.14
14.3 CBU1290 DnaK chaperone 485 17% 7 70.7/5.14
CBU0235 FusA elongation factor EF-G 167 8% 4 77.7/5.07
14.4 CBU1290 DnaK chaperone 644 34% 11 70.7/5.14
14.5 CBU1290 DnaK chaperone 637 24% 11 70.7/5.14
CBU0235 FusA elongation factor EF-G 129 3% 2 77.7/5.07
15.1 CBU1718 GroEL chaperonin 196 26% 3 58.2/5.14
15.3 CBU0215 Peptidase C40/NplC-P60 family 105 13% 2 58.0/6.06
15.4 CBU0215 Peptidase C40/NplC-P60 family 239 26% 4 58.0/6.06
15.5 CBU0215 Peptidase C40/NplC-P60 family 231 17% 5 58.0/6.06
CBU1398 SucB dihydrolipoamide succinyltransferase 105 10% 2 45.9/5.54
15.6 CBU0215 Peptidase C40/NplC-P60 family 183 25% 2 58.0/6.06
CBU1398 SucB dihydrolipoamide succinyltransferase 61 24% 1 45.9/5.54
15.7 CBU1398 SucB dihydrolipoamide succinyltransferase 103 14% 2 45.9/5.54
CBU0932 GplK glycerol kinase 93 10% 2 55.3/5.46
CBU0572 Cytosol aminopeptidase 86 18% 1 51.0/5.56
CBU0215 Peptidase C40/NplC-P60 family 65 11% 1 58.0/6.06
15.8 CBU0215 Peptidase C40/NplC-P60 family 114 13% 2 58.0/6.06
CBU1398 SucB dihydrolipoamide succinyltransferase 87 12% 2 45.9/5.54
16.2 CBU0236 Elongation factor EF-Tu 877 65% 14 43.5/5.32
16.3 CBU0236 Elongation factor EF-Tu 789 64% 12 43.5/5.32
16.4 CBU0236 Elongation factor EF-Tu 1120 77% 18 43.5/5.32
17 CBU0236 Elongation factor EF-Tu 75 26% 1 43.5/5.32
18 CBU1241 Mdh malate dehydrogenase 160 11% 2 35.4/5.07
19 CBU0092 Tol system component YbgF 250 39% 5 32.0/5.49
19.1 CBU1396 SucD succinyl-CoA synthetase, alpha subunit 68 7% 2 30.6/5.38
20 CBU0092 Tol system component YbgF 154 35% 4 32.0/5.49
20.1 CBU1396 SucD succinyl-CoA synthetase, alpha subunit 399 35% 7 30.6/5.38
23 CBU1385 Elongation factor EF-Ts 327 40% 8 31.8/5.85
24 CBU0528 RpsA ribosomal protein S1 280 13% 5 62.1/5.28
26 CBU0858 NadE NAD
+ synthase glutamine-dependent 632 26% 12 60.3/5.63
27 CBU1943 ATP synthase F1, alpha subunit 153 9% 2 56.8/5.80
28 CBU0103 Peptidase, M20A family 347 27% 6 52.8/5.35
29 CBU0103 Peptidase, M20A family 562 37% 10 52.8/5.35
34 CBU0750 Arabinose-5-phosphate isomerase 174 15% 2 34.5/6.79
38 CBU1910 com1 211 30% 4 27.6/9.08
CBU1260 OmpA-like protein 99 16% 1 26.2/9.61
CBU0307 OmpA-like protein 84 15% 1 24.9/9.91
NS CBU1718 GroEL chaperonin 511 45% 8 58.2/5.14
N43 CBU0263 RpoA RNA polymerase, alpha subunit 338 25% 5 35.5/5.61
*Corresponds to spot shown in Fig. 3.
DTIGR annotation.
dDescribed in Beare et al. (2009), Supplemental file 1, Supplemental Table S5.
§Mascot protein scores (standard scoring) are derived from combined peptide ion scores as a non-probabilistic basis for ranking protein hits.
||The number of unique peptides identified with ion scores .24 that indicate identity or extensive homology (P,0.05). Ion score is 2106log(P),
where P is the probability that the match is a random event.
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CBU1718 (GroEL) with an apparent molecular mass and
pI that matched the predicted values in contrast to its
migration in spot 15.1. The amount of GroEL in spot NS
and its weak seroreactivity make it unlikely that the
reactivity of the much less abundant spot 15.1 would be
due to GroEL.
The prominent immune sera-reactive spots identified as
CBU1910 (com1) on pH 3–10 blots were not as evident on
pH 5–8 immune sera-probed blots. Only one strongly
reactive spot, spot 38, was identified as CBU1910 (com1).
The expected pI of CBU1910 (com1) is 9.08 and therefore
outside the pH range of pH 5–8 gradient strips, and the
higher-pI isoforms of com1 may have migrated out of the
IPG strip (Poznanovic et al., 2005).
Blots probed with sham sera reacted very strongly with
three spots migrating with same apparent molecular mass
but different pIs, identical to the pH 3–10 sham sera-
probed blots, and were similarly designated spots N41, N42
and N43. The spot-matching function of PDQuest aligned
these spots just to the cathode side of spot 20.1. However,
only spot N43 could be unambiguously matched on the
corresponding gel and was identified as CBU0263 (RpoA).
2D Electrophoresis, immunoblotting, and LC-MS/
MS identification of phase I (L929) proteins
separated on pH 5–8 gradient gels
Since a high percentage of reactive spots from phase I (egg)
extracts were identified as Gallus proteins, whole-cell
extracts of phase I grown in murine L929 cells were
assayed. Due to the limited quantity of phase I (L929) cells,
extracted protein was sufficient for only two pH 5–8
gradient gels. One gel was used for spot harvesting and the
other was transferred and probed with immune sera. The
stained pH 5–8 gradient gel is shown in Fig. 4(a). The
numbered spots on the gel correspond to matched
seroreactive spots detected on the immune sera-probed
blot shown in Fig. 4(b). Reactive C. burnetii proteins
identified by LC-MS/MS are listed in Table 4.
The strongly reactive spots 2–2.6 were identified as
CBU1290 (DnaK) and CBU0235 (EF-G), with only
CBU1290 identified in spots 2.5 and 2.6. All spots in the
16 series were identified as CBU0236 (EF-Tu). A series of
strongly reactive doublet spots corresponding to spots
15.1–15.8 were also evident. Manually excising spots 15.1
and 15.2 resulted in both spots being excised in the same
gel piece at which point the individual spots could not be
separated. Consequently, spots 15.1 and 15.2 were analysed
by LC-MS/MS together, designated spot 15.1.2, and
identified as CBU1718 (GroEL), CBU1398 (SucB) and
CBU0215 (peptidase). Similar to previous LC-MS/MS
analyses of the 15 series of spots, CBU1398 (SucB) and
CBU0215 (peptidase) were identified across the series of
spots and generally were identified together. Additionally,
CBU0932 (glycerol kinase) and CBU0572 (cytosol amino-
peptidase) were identified in spots 15.5 and 15.7. Also, spot
15.9 in this series displayed stronger immune sera reactivity
on this blot and was identified as CBU0932 (glycerol
kinase). Upon examination of previous immune sera-
probed blots, a reactive spot analogous to spot 15.9 was
distinguishable, although with less reactivity than on the
present blot.
Immune sera-reactive spots 13 and 19 were identified as
CBU1241 (malate dehydrogenase). Spots 12, 18, 20 and 23
all migrated with the same apparent molecular mass and all
were identified as CBU0092 (Tol system component YbgF).
Spot 24 was identified as CBU1396 (SucD). Spot 30,
identified as CBU1385 (EF-Ts), had greater immune sera
reactivity on this immunoblot than other immune sera-
probed blots. The immune sera reactivity of spot 27 was
diffuse but had a slightly defined focus, which was
harvested as spot 27 and identified as CBU1706 (thior-
edoxin peroxidase). Weakly reactive spot 17 was identified
as CBU0140 (cell division protein FtsA). Very strong
reactivity was seen at the cathode edge (unlabelled circle),
and had been consistently identified as CBU1910 on
previous phase I and phase II pH 5–8 gradient gels, but was
not harvested from this gel for LC-MS/MS analysis.
Summary of C. burnetii Nine Mile proteins
identified in immunogenic 2D spots
Most reactive proteins were identified on multiple blots.
However, CBU0140 (FtsA), CBU0299 (RNase PH),
CBU0528 (ribosomal protein S1), CBU0750 (arabinose-5-
phosphate isomerase), CBU0858 (glutamine-dependent
NAD
+ synthase), CBU1718 (GroEL) and CBU1943 (ATP
synthase F1, alpha subunit) had sufficient intensity to be
deemed immunoreactive on only one blot. CBU0103
(peptidase, M20A) was identified from one gel but was
detectableonmultiplepH 5–8gradientimmunesera-probed
blots. A summary of the C. burnetii proteins identified in
immune sera-reactive spots is shown in Table 5. CBU0229
(ribosomal protein L7/L12) was reactive with both immune
sera and sham sera and is omitted from Table 5.
Immunoreactive spots in the 15 series co-identified as
CBU0215 (peptidase) and CBU1398 (SucB), and a definitive
assignment of seroreactivity to either was not possible.
Similarly, CBU0572 (cytosol aminopeptidase), CBU0235
(EF-G), CBU0482 (arginine-binding protein), CBU0495
(FabG), CBU1227 (transcriptional regulatory protein
QseB), CBU0307 (OmpA-like), CBU0481 (arginine trans-
port ATP-binding protein), CBU0780/CBU0955 (response
regulator GacA) and CBU1260 (OmpA-like) were co-
identified with seroreactive proteins, and their seroreactivity
also cannot be conclusively determined in this study.
DISCUSSION
Nine novel seroreactive C. burnetii Nine Mile proteins were
identified in the present study. Seven displayed good
J. R. Deringer and others
536 Microbiology 157reactivity with immune sera, CBU0932 (glycerol kinase),
CBU1241 (malate dehydrogenase), CBU1396 (SucD),
CBU1385 (EF-Ts), CBU0299 (RNase PH), CBU0750
(arabinose-5-phosphate isomerase) and CBU0103 (pepti-
dase, M20A family), while two were detected with fairly
low reactivity, CBU0140 (cell division protein FtsA) and
CBU0858 (glutamine-dependent NAD
+ synthase). Eight
other immune sera-reactive proteins identified in the
present study were identified by Sekeyova ´ et al. (2009) as
reactive with sera from humans infected with C. burnetii
using a 2D immunoproteomics platform: CBU0092 (Tol
component YbgF), CBU0236 (EF-Tu), CBU0937 (hypo-
thetical exported protein), CBU1290 (DnaK), CBU1706
(thioredoxin peroxidase), CBU1718 (GroEL) and
CBU1910 (com1). Sekeyova ´ et al. (2009) also identified
CBU0235 (EF-G), CBU0572 (cytosol aminopeptidase),
CBU0307 (OmpA-like) and CBU1260 (OmpA-like) as
seroreactive. While we were able to identify these four
Fig. 4. Whole-cell extracts of C. burnetii RSA 493 phase I grown in mouse L929 cell culture and separated by 2D gel
electrophoresis on pH 5–8 IEF gradients and 10.5–14% acrylamide SDS-PAGE gels. C. burnetii seroreactive proteins are
listed in Table 4. Molecular mass standards (kDa) are indicated on the left. (a) Sypro Ruby-stained gel showing seroreactive
spots. (b) Immunoblot probed with pooled immune guinea pig serum.
Immunoreactive Coxiella burnetii proteins
http://mic.sgmjournals.org 537Table 4. Phase I (L929) C. burnetii Nine Mile proteins identified by LC-MS/MS in seroreactive spots separated on pH 5–8 gradient
gels
Spot
no.*
Locus tagD Putative proteind Protein
score§
Sequence
coverage
No. of unique
peptides with
P value ,0.05||
Predicted Mr
(kDa)/pI
2 CBU0235 FusA elongation factor EF-G 189 9% 3 77.7/5.07
CBU1290 DnaK chaperone 59 7% 1 70.7/5.14
2.1 CBU0235 FusA elongation factor EF-G 223 18% 4 77.7/5.07
CBU1290 DnaK chaperone 135 11% 2 70.7/5.14
2.2 CBU1290 DnaK chaperone 420 20% 8 70.7/5.14
CBU0235 FusA elongation factor EF-G 270 12% 6 77.7/5.07
2.3 CBU1290 DnaK chaperone 660 32% 13 70.7/5.14
CBU0235 FusA elongation factor EF-G 144 8% 2 77.7/5.07
2.4 CBU1290 DnaK chaperone 367 24% 5 70.7/5.14
CBU0235 FusA elongation factor EF-G 57 2% 1 77.7/5.07
2.5 CBU1290 DnaK chaperone 183 11% 5 70.7/5.14
2.6 CBU1290 DnaK chaperone 211 16% 3 70.7/5.14
12 CBU0092 Tol system component YbgF 76 9% 1 32.0/5.49
13 CBU1241 Mdh malate dehydrogenase 40 6% 1 35.4/5.07
15.1.2 CBU1718 GroEL chaperonin 383 29% 5 58.2/5.14
CBU1398 SucB dihydrolipoamide succinyltransferase 109 11% 3 45.9/5.54
CBU0215 Peptidase, C40/NplC-P60 family 40 1% 1 58.0/5.14
15.3 CBU1398 SucB dihydrolipoamide succinyltransferase 107 9% 2 45.9/5.54
CBU1718 GroEL chaperonin 105 9% 2 58.2/5.14
CBU0215 Peptidase, C40/NplC-P60 family 42 5% 1 58.0/5.14
15.4 CBU1398 SucB dihydrolipoamide succinyltransferase 258 22% 5 45.9/5.54
CBU1718 GroEL chaperonin 93 6% 1 58.2/5.14
CBU0215 Peptidase, C40/NplC-P60 family 85 6% 2 58.0/5.14
15.5 CBU1398 SucB dihydrolipoamide succinyltransferase 165 15% 2 45.9/5.54
CBU0932 GplK glycerol kinase 64 2% 1 55.3/5.46
CBU0572 Cytosol aminopeptidase 59 5% 2 50.8/5.56
CBU0215 Peptidase, C40/NplC-P60 family 39 1% 1 58.0/6.06
15.6 CBU0215 Peptidase, C40/NplC-P60 family 84 4% 2 58.0/6.06
15.7 CBU1398 SucB dihydrolipoamide succinyltransferase 150 14% 3 45.9/5.54
CBU0932 GplK glycerol kinase 62 2% 1 55.3/5.46
CBU0572 Cytosol aminopeptidase 33 2% 1 50.8/5.56
15.8 CBU1398 SucB dihydrolipoamide succinyltransferase 63 11% 2 45.9/5.54
15.9 CBU0932 GplK glycerol kinase 94 5% 1 55.3/5.46
16 CBU0236 Elongation factor EF-Tu 192 27% 3 43.5/5.32
16.1 CBU0236 Elongation factor EF-Tu 408 45% 8 43.5/5.32
16.2 CBU0236 Elongation factor EF-Tu 613 53% 11 43.5/5.32
16.4 CBU0236 Elongation factor EF-Tu 495 42% 10 43.5/5.32
17 CBU0140 Cell division protein FtsA 91 8% 3 44.3/5.79
18 CBU0092 Tol system component YbgF 84 16% 1 32.0/5.49
19 CBU1241 Mdh malate dehydrogenase 200 17% 4 35.4/5.07
20 CBU0092 Tol system component YbgF 73 9% 2 32.0/5.49
23 CBU0092 Tol system component YbgF 80 7% 2 32.0/5.49
24 CBU1396 SucD succinyl-CoA synthetase, alpha 206 31% 2 30.6/5.38
27 CBU1706 Thioredoxin peroxidase, AhpC/Tsa family 46 5% 1 21.8/5.08
30 CBU1385 Elongation factor EF-Ts 399 55% 6 31.8/5.85
*Corresponds to spot shown in Fig. 4.
DTIGR annotation.
dDescribed in Beare et al. (2009), Supplemental file 1, Supplemental Table S5.
§Mascot protein scores (standard scoring) are derived from combined peptide ion scores as a non-probabilistic basis for ranking protein hits.
||The number of unique peptides identified with ion scores .24 that indicate identity or extensive homology (P,0.05). Ion score is 2106log(P),
where P is the probability that the match is a random event.
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unable to conclusively assign reactivity due to their co-
identification with proteins that were determined to be
immune sera-reactive.
Several reactive proteins identified in this study were also
reactive against convalescent human sera in other studies.
Coleman et al. (2007) used a 2D platform to identify
CBU0236 (EF-Tu), CBU1718 (GroEL), CBU1943 (ATP
synthase F1, alpha subunit) and CBU0229 (ribosomal
protein L7/L12) as seroreactive. Using a protein array
platform, CBU1398 (SucB), CBU0307 (OmpA-like),
CBU1910 (com1), CBU0092 (Tol system YbgF) and
CBU0229 (L7/L12) were identified as immunoreactive
with Q fever patient sera (Beare et al., 2008; Vigil et al.,
2010). Vigil et al. (2010) also found CBU1290 (DnaK) to be
strongly reactive with some patient sera but also strongly
reactive against one naı ¨ve-group serum. The reactivity of
CBU1398 (SucB) demonstrated in previous studies sug-
gests that this protein is responsible for the reactivity seen
in spots that comprised additional co-identified proteins in
the present study. The similarity in antibody response
between humans and guinea pigs against C. burnetii
antigens supports the use of guinea pigs as an animal
model for Q fever subunit vaccine studies.
The finding that sham sera reacted strongly with CBU0263
(RpoA) and CBU0229 (L7/L12) was somewhat of a
surprise, and may be due to an antibody response to a
microbial protein homologue originating from the normal
Table 5. Summary of C. burnetii Nine Mile proteins specific to immune sera-reactive 2D spots
Locus tag* Putative proteinD Found in phase I, phase
II or both
Human
sera-reactived
Immunoreactive proteins
CBU0092 Tol system periplasmic component YbgF I 1,2
CBU0103 Peptidase, M20A family II
CBU0236 Elongation factor EF-Tu Both 1,3
CBU0299 Rph RNase PH II
CBU0750 Arabinose-5-phosphate isomerase II
CBU0932 GplK glycerol kinase Both
CBU0937 Hypothetical exported protein II 1
CBU1241 Mdh malate dehydrogenase Both
CBU1290 DnaK chaperone Both 1,2
CBU1385 Elongation factor EF-Ts Both
CBU1396 SucD, succinyl-CoA synthetase alpha chain Both
CBU1398 SucB, dihydrolipoamide succinyltransferase E2 of
2-oxoglutarate dehydrogenase complex
Both 2,4
CBU1706 Thioredoxin peroxidase, AhpC/Tsa antioxidant I 1
CBU1910 com1 outer-membrane protein Both 1,2
Weakly immunoreactive proteins
CBU0140 Cell division protein FtsA I
CBU0528 Ribosomal protein S1P (RpsA) II 1
CBU0858 NAD
+ synthase, glutamine-dependent II
CBU1718 GroEL chaperonin Both 1,3,5
CBU1943 ATP synthase F1, alpha subunit II 3
Proteins co-identified with a protein
listed above
CBU0215 Peptidase, C40/NplC-P60 family Both
CBU0235 FusA elongation factor EF-G Both 1
CBU0307 OmpA-like outer-membrane protein II 1,4
CBU0481 Arginine transport ATP-binding protein ArtP II
CBU0482 Arginine-binding protein, periplasmic II
CBU0495 3-Oxoacyl-ACP reductase FabG I
CBU0572 Cytosol aminopeptidase Both 1
CBU0780, CBU0955 Response regulator GacA I
CBU1227 Transcriptional regulatory protein QseB II
CBU1260 OmpA-like transmembrane domain protein II 1
*TIGR annotation.
DDescribed in Beare et al. (2009), Supplemental file 1, Supplemental Table S5.
dReferences: 1, Sekeyova ´ et al. (2009); 2, Vigil et al. (2010); 3, Coleman et al. (2007); 4, Beare et al. (2008); 5, Williams et al. (1990).
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http://mic.sgmjournals.org 539guinea pig flora. Interestingly, Bartonella henselae ribo-
somal protein L7/L12 is reactive with serum from healthy
human donors (Eberhardt et al., 2009).
CBU1718 (GroEL) has frequently been detected as reactive
with immune sera. Despite being a very abundant protein
on all gels in the present study, it was weakly reactive on
only one immunoblot. Interestingly, Williams et al. (1990)
found that convalescent and chronic-phase Q fever human
sera both reacted with C. burnetii heat-shock protein HtpB
(GroEL), although acute-phase sera did not.
Most immunoreactive proteins identified in this study have
experimental molecular masses and pIs that are near their
theoretical values, and their locations are in general
agreement with those of other proteins identified in 2D
proteomic reference maps of C. burnetii Nine Mile
(Samoilis et al., 2007; Sekeyova ´ et al., 2009). The most
notable exception is the apparent molecular mass of
CBU1718 (GroEL) identified in spot 15.1. This molecular
mass is less than the expected molecular mass of GroEL
which was identified in the spot labelled NS and focused
where expected. Interestingly, a lower-molecular-mass
GroEL isoform has also been identified in Brucella abortus
and migrates with a molecular mass and pI similar to those
of GroEL identified in spot 15.1 (Connolly et al., 2006).
The location where CBU0215 (peptidase) was consistently
identified is at a molecular mass approximately 8 kDa less
than expected, which may reflect potential processing to
the mature form, the use of a start or stop codon different
from that used for the predictive protein calculations, or
protein degradation. The immune sera-reactive spot
identified as CBU0299 (ribonuclease PH) had a theoretical
molecular mass of 26 kDa but migrated with an experi-
mental molecular mass that appeared closer to 30 kDa.
CBU1910 (com1) has a theoretical molecular mass of
27.6 kDa but migrates with an apparent molecular mass of
25.7 kDa due to cleavage of the leader sequence, in
agreement with our results (Hendrix et al., 1993).
The proteins identified as immunoreactive have a variety of
functions and most have been associated with the
membrane or cell wall. Multiple proteins identified as
immunoreactive are involved in carbon metabolism.
CBU1398 (SucB), CBU1396 (SucD) and CBU1241 (malate
dehydrogenase) catalyse reactions in the formation of
oxaloacetate from succinyl-CoA, and CBU0932 (glycerol
kinase) functions in the utilization of carbon from lipids.
While generally considered cytosolic proteins, the asso-
ciation of these carbon-metabolizing proteins with cell
membranes has been described for a number of intracel-
lular pathogens (Connolly et al., 2006; Boonjakuakul et al.,
2007; Janovska ´ et al., 2007). CBU0092 is the periplasmic
component YbgF of the Tol–Pal system involved in
maintaining outer membrane integrity. CBU0937 is a
hypothetical exported protein that has an unknown
function. CBU0103 (peptidase) belongs to the M20A
peptidase family. Members of the M20A peptidase family
have diverse specificities, but protein BLAST analysis of
CBU0103 shows the most identity (59%) to succinyl-
diaminopimelate desuccinylase. CBU0750 (arabinose-5-
phosphate isomerase) catalyses the interconversion of
ribulose 5-phosphate and arabinose 5-phosphate, and is
required for the synthesis of the 3-deoxy-D-manno-
octulosonic acid (Kdo) component of LPS (Tzeng et al.,
2002). CBU0858 (glutamine-dependent NAD
+ synthase)
amidates nicotinic acid adenine dinucleotide (NaAD
+)t o
NAD
+, which is involved in a diverse range of redox
reactions. CBU0299 (RpH RNase PH) is an exonuclease
that generates mature tRNA by removal of an excess RNA
extension on the 39 end of tRNA. CBU1290 (DnaK)
belongs to the heat-shock protein 70 family (Hsp70) and is
highly conserved among prokaryotes and eukaryotes.
Hsp70 functions as a molecular chaperone and in the
transport of proteins across membranes. DnaK can be
membrane-associated in pathogenic bacteria and partici-
pates in binding to the host cell surface, which may
facilitate cellular invasion (Knaust et al., 2007; Xolalpa et al.,
2007). CBU0236 (EF-Tu), CBU1385 (EF-Ts) and CBU0528
(ribosomal protein S1) are involved in protein translation.
EF-Tu may function as a cytoskeleton component,
maintaining the shape of prokaryotes (Mayer, 2003). EF-
Tu can also be surface-exposed and bind to host cell
surfaces, potentially facilitating intracellular invasion
(Balasubramanian et al., 2008; Barel et al., 2008).
CBU0528 (S1) is a component of the 30S ribosome and
can be associated with membranes or free in the cytosol,
depending on the destination of the nascent peptide.
The cross-reactivity of C. burnetii proteins is problematic
for the serodiagnosis of Q fever. C. burnetii antisera cross-
react with recombinant SucB from Bartonella vinsonii
subsp. burkhoffii (Gilmore et al., 2003), and antisera against
Escherichia coli EF-G and ribosomal protein L7/L12 are
cross-reactive with C. burnetii homologues (Baca, 1978).
Additionally, a monoclonal antibody directed against
CBU0236 (EF-Tu) cross-reacts with recombinant EF-Tu
from Chlamydia trachomatis (Seshadri et al., 1999). The
identification of immunogenic C. burnetii proteins with
low homology to other proteins is paramount for the
unambiguous serodiagnosis of Q fever. CBU0092 (Tol–Pal
component YbgF) and CBU0937 (hypothetical exported
protein) have low identities to other proteins (34% for
both), and may provide additional stringency in the
serodiagnosis of Q fever.
The number of Q fever subunit vaccine studies is fairly
limited. A native purified 67 kDa C. burnetii protein is
protective in both mice and guinea pigs (Zhang et al.,
1994), and Williams et al. (1990) found that native purified
CBU0311 (P1) induces a protective response in mice.
However, recombinant C. burnetii CBU1910 (com1),
CBU0311 (P1), CBU0630 (Cb-Mip) and P28 are unable
to protect mice from subsequent challenge (Zhang &
Samuel, 2003). Shannon & Heinzen (2009) have proposed
that the protection induced by native but not recombinant
C. burnetii antigens may be due to the requirement for
native epitopes or other protective Coxiella antigens,
J. R. Deringer and others
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Interestingly, contaminating Francisella tularensis LPS has
been found to be required for protection when using
Hsp60 (GroEL) purified from F. tularensis (Hartley et al.,
2004). Additionally, a recombinant fusion protein of
CBU0311 (P1) and CBU1718 (GroEL) is protective in
mice, while individual recombinant P1 and GroEL are not
(Li et al., 2005), indicating that an effective subunit vaccine
against Q fever may require multiple antigenic subunits.
Clearly there is a need to identify and characterize
additional C. burnetii antigens in order to expedite the
development of a safe and efficacious Q fever subunit
vaccine. The C. burnetii immunoreactive antigens iden-
tified in the present study may represent potential subunit
vaccine candidates. Induction of an IgG response suggests
the involvement of T cells, which are required for the
development of a protective immune response against C.
burnetii (Zhang et al., 2007). T cell responses to these
antigens need to be characterized to further validate their
potential as subunit vaccine candidates.
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